Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Mainz Biomed (NASDAQ:MYNZ) is marking Colorectal Cancer Awareness Month with a focus on transforming screening into prevention. The company highlights that colorectal cancer (CRC) remains the second leading cause of cancer deaths globally, causing over 930,000 deaths annually, with 150,000 diagnoses in the U.S. and 22,836 deaths in Germany.
The company's research has yielded promising results through their ColoFuture and eAArly DETECT studies, achieving 82% sensitivity in advanced adenoma detection with 97% specificity using mRNA biomarkers, FIT test, and AI algorithms. Their flagship product, ColoAlert®, is expanding through laboratory partnerships, including a recent collaboration in Switzerland.
To increase accessibility, Mainz Biomed has implemented at-home testing solutions through European Oncology Lab's web platform. The company emphasizes that while CRC is highly preventable, low screening participation continues to make it a leading cause of cancer deaths, driving their mission to enhance early detection and prevention strategies.
Mainz Biomed (NASDAQ:MYNZ) sta celebrando il Mese della Consapevolezza sul Cancro Colorettale con un focus sulla trasformazione dello screening in prevenzione. L'azienda sottolinea che il cancro colorettale (CRC) rimane la seconda causa principale di morte per cancro a livello globale, causando oltre 930.000 decessi annuali, con 150.000 diagnosi negli Stati Uniti e 22.836 decessi in Germania.
La ricerca dell'azienda ha prodotto risultati promettenti attraverso i loro studi ColoFuture e eAArly DETECT, raggiungendo l'82% di sensibilità nella rilevazione di adenomi avanzati con il 97% di specificità utilizzando biomarcatori mRNA, test FIT e algoritmi di intelligenza artificiale. Il loro prodotto di punta, ColoAlert®, si sta espandendo attraverso partnership di laboratorio, inclusa una recente collaborazione in Svizzera.
Per aumentare l'accessibilità, Mainz Biomed ha implementato soluzioni di test a domicilio attraverso la piattaforma web dell'European Oncology Lab. L'azienda enfatizza che, sebbene il CRC sia altamente prevenibile, la bassa partecipazione agli screening continua a farne una delle principali cause di morte per cancro, spingendo la loro missione a migliorare le strategie di rilevazione precoce e prevenzione.
Mainz Biomed (NASDAQ:MYNZ) está marcando el Mes de la Concienciación sobre el Cáncer Colorrectal con un enfoque en transformar la detección en prevención. La empresa destaca que el cáncer colorrectal (CRC) sigue siendo la segunda causa principal de muertes por cáncer a nivel mundial, causando más de 930,000 muertes anuales, con 150,000 diagnósticos en EE. UU. y 22,836 muertes en Alemania.
La investigación de la empresa ha arrojado resultados prometedores a través de sus estudios ColoFuture y eAArly DETECT, logrando un 82% de sensibilidad en la detección de adenomas avanzados con un 97% de especificidad utilizando biomarcadores de ARNm, pruebas FIT y algoritmos de IA. Su producto insignia, ColoAlert®, se está expandiendo a través de asociaciones de laboratorio, incluida una reciente colaboración en Suiza.
Para aumentar la accesibilidad, Mainz Biomed ha implementado soluciones de pruebas en casa a través de la plataforma web del European Oncology Lab. La empresa enfatiza que, aunque el CRC es altamente prevenible, la baja participación en las pruebas sigue siendo una de las principales causas de muerte por cáncer, impulsando su misión de mejorar las estrategias de detección temprana y prevención.
Mainz Biomed (NASDAQ:MYNZ)는 대장암 인식의 달을 기념하며 검진을 예방으로 전환하는 데 주력하고 있습니다. 이 회사는 대장암(CRC)이 전 세계적으로 암 사망의 두 번째 주요 원인으로 남아 있으며, 매년 930,000명 이상의 사망자를 초래하고 있으며, 미국에서 150,000건의 진단과 독일에서 22,836명의 사망자를 초래하고 있다고 강조합니다.
회사의 연구는 ColoFuture 및 eAArly DETECT 연구를 통해 유망한 결과를 도출했으며, mRNA 바이오마커, FIT 테스트 및 AI 알고리즘을 사용하여 고급 선종 발견에서 82%의 민감도와 97%의 특이도를 달성했습니다. 그들의 주력 제품인 ColoAlert®는 최근 스위스에서의 협력을 포함하여 실험실 파트너십을 통해 확장되고 있습니다.
접근성을 높이기 위해 Mainz Biomed는 유럽 종양학 연구소의 웹 플랫폼을 통해 자택 검사 솔루션을 구현했습니다. 이 회사는 CRC가 매우 예방 가능하지만 낮은 검진 참여율이 여전히 암 사망의 주요 원인 중 하나로 남아 있다고 강조하며, 조기 발견 및 예방 전략을 강화하는 임무를 추진하고 있습니다.
Mainz Biomed (NASDAQ:MYNZ) célèbre le Mois de la Sensibilisation au Cancer Colorectal en se concentrant sur la transformation du dépistage en prévention. L'entreprise souligne que le cancer colorectal (CRC) reste la deuxième cause de décès par cancer dans le monde, entraînant plus de 930 000 décès par an, avec 150 000 diagnostics aux États-Unis et 22 836 décès en Allemagne.
Les recherches de l'entreprise ont produit des résultats prometteurs grâce à leurs études ColoFuture et eAArly DETECT, atteignant 82 % de sensibilité dans la détection des adénomes avancés avec 97 % de spécificité en utilisant des biomarqueurs d'ARNm, des tests FIT et des algorithmes d'IA. Leur produit phare, ColoAlert®, s'étend grâce à des partenariats de laboratoire, y compris une collaboration récente en Suisse.
Pour accroître l'accessibilité, Mainz Biomed a mis en œuvre des solutions de test à domicile via la plateforme web de l'European Oncology Lab. L'entreprise souligne que, bien que le CRC soit fortement évitable, la faible participation aux dépistages continue d'en faire l'une des principales causes de décès par cancer, ce qui pousse leur mission à améliorer les stratégies de détection précoce et de prévention.
Mainz Biomed (NASDAQ:MYNZ) feiert den Monat zur Sensibilisierung für Darmkrebs mit dem Fokus darauf, Screening in Prävention umzuwandeln. Das Unternehmen hebt hervor, dass Darmkrebs (CRC) weltweit die zweithäufigste Todesursache durch Krebs bleibt und jährlich über 930.000 Todesfälle verursacht, mit 150.000 Diagnosen in den USA und 22.836 Todesfällen in Deutschland.
Die Forschung des Unternehmens hat vielversprechende Ergebnisse durch die Studien ColoFuture und eAArly DETECT erzielt, mit 82% Sensitivität bei der Erkennung von fortgeschrittenen Adenomen und 97% Spezifität unter Verwendung von mRNA-Biomarkern, FIT-Tests und KI-Algorithmen. Ihr Flaggschiffprodukt, ColoAlert®, wird durch Laborpartnerschaften erweitert, einschließlich einer kürzlichen Zusammenarbeit in der Schweiz.
Um die Zugänglichkeit zu erhöhen, hat Mainz Biomed Lösungen für Tests zu Hause über die Webplattform des European Oncology Lab implementiert. Das Unternehmen betont, dass, obwohl CRC hochgradig vermeidbar ist, die niedrige Teilnahme an Screenings weiterhin eine der Hauptursachen für Krebstodesfälle darstellt, was ihre Mission antreibt, Strategien zur frühzeitigen Erkennung und Prävention zu verbessern.
- None.
- None.
BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to support Colorectal Cancer Awareness Month in March. Detecting colorectal cancer (CRC) in its early stages significantly improves survival rates, making awareness and proactive screening essential in the fight against this disease. Globally, CRC is the second leading cause of cancer-related deaths, with over 930,000 fatalities annually. In the U.S. it is estimated that over 150,000 people were diagnosed with colorectal cancer, and in Germany, approximately 22,836 individuals succumb to CRC each year, accounting for a substantial portion of cancer-related mortality in the country.
Mainz Biomed is committed to combating CRC by advancing diagnostic solutions that focus on early intervention rather than late-stage detection. Through ongoing research, the Company aims to transform the CRC landscape with its next generation product, enabling early detection of pre-cancerous adenomas to improve prevention strategies. Leveraging a combination of mRNA biomarkers, the FIT test, and a proprietary AI algorithm, Mainz Biomed’s pooled analysis of the ColoFuture and eAArly DETECT studies demonstrated a groundbreaking advanced adenoma detection sensitivity of
With the current flagship product, ColoAlert®, Mainz Biomed already is enhancing the CRC screening landscape by expanding collaborations with laboratories, including its most recent partnership in Switzerland. By fostering these partnerships, the company is making high-quality, DNA-based screening more widely accessible.
Lowering barriers to CRC screening is crucial in empowering both patients and healthcare professionals in early cancer detection. One key initiative is increasing accessibility through at-home testing solutions, now available via one of Mainz Biomed’s laboratory partners, European Oncology Lab, through their web-based platform.
Colorectal Cancer Awareness Month serves as a crucial reminder that early detection saves lives. Despite being one of the most preventable cancers, CRC remains a leading cause of cancer-related deaths worldwide due to low screening participation. Mainz Biomed is committed to changing this by driving awareness, expanding access to cutting-edge screening solutions, and empowering individuals to take proactive steps in their health. By fostering education, innovation, and accessibility, the Company continues to champion a future where colorectal cancer is detected early—and, ultimately, prevented.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Anne Hennecke / Simone Neeten
+49 211 529252 17
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What are the key findings from Mainz Biomed's (MYNZ) ColoFuture and eAArly DETECT studies?
How is Mainz Biomed (MYNZ) making colorectal cancer screening more accessible?
What is the current global impact of colorectal cancer according to Mainz Biomed's report?
How is Mainz Biomed (MYNZ) expanding its ColoAlert® product availability in 2025?
What are the colorectal cancer statistics for the U.S. and Germany mentioned in MYNZ's report?
